Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 15;98(2):325–335. doi: 10.1172/JCI118796

Renal expression of tissue factor pathway inhibitor and evidence for a role in crescentic glomerulonephritis in rabbits.

J H Erlich 1, J Apostolopoulos 1, T C Wun 1, K K Kretzmer 1, S R Holdsworth 1, P G Tipping 1
PMCID: PMC507434  PMID: 8755641

Abstract

Tissue factor pathway inhibitor (TFPI) was demonstrated in the kidneys of normal rabbits and in a crescentic model of glomerulonephritis (GN), where fibrin is a key mediator of injury. In normal kidneys, TFPI was expressed in glomeruli, in intrarenal arteries and the interstitial capillary network. Evidence for TFPI synthesis in vivo was provided by in situ demonstration of TFPI mRNA in glomeruli and intrarenal vessels and by biosynthetic labeling of TFPI released from glomeruli in vitro. In fibrin-dependent crescentic GN, glomerular TFPI synthesis and expression was initially decreased (TFPI antigen at 24 h, 7.5 +/- 0.7 ng/10(3) glomeruli; normal, 11.1 +/- 0.9 ng/10(3) glomeruli, P < 0.02) and subsequently returned to normal values. Plasma TFPI levels increased progressively throughout the evolution of disease. In vivo inhibition of TFPI using an anti-TFPI antibody during the development of GN significantly increased glomerular fibrin deposition (GFD) and exacerbated renal impairment. Infusion of recombinant human TFPI significantly reduced development of GFD (fibrin scores, TFPI treated 0.82 +/- 0.11, control 1.49 +/- 0.14, P < 0.01), proteinuria and renal impairment. This data indicates that TFPI is synthesized and expressed in normal glomeruli and is down regulated in the early response to glomerular injury. Endogenous glomerular TFPI and treatment with recombinant TFPI reduces GFD and injury in fibrin dependent GN. TFPI has the potential to be of therapeutic benefit in the management of fibrin dependent human GN.

Full Text

The Full Text of this article is available as a PDF (916.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ameri A., Kuppuswamy M. N., Basu S., Bajaj S. P. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood. 1992 Jun 15;79(12):3219–3226. [PubMed] [Google Scholar]
  2. Apostolopoulos J. J., Howlett G. J., Fidge N. Effects of dietary cholesterol and hypothyroidism on rat apolipoprotein mRNA metabolism. J Lipid Res. 1987 Jun;28(6):642–648. [PubMed] [Google Scholar]
  3. Bajaj M. S., Rana S. V., Wysolmerski R. B., Bajaj S. P. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest. 1987 Jun;79(6):1874–1878. doi: 10.1172/JCI113030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Border W. A., Wilson C. B., Dixon F. J. Failure of heparin to affect two types of experimental glomerulonephritis in rabbits. Kidney Int. 1975 Sep;8(3):140–148. doi: 10.1038/ki.1975.93. [DOI] [PubMed] [Google Scholar]
  5. Broze G. J., Jr The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol. 1992 Jul;29(3):159–169. [PubMed] [Google Scholar]
  6. Broze G. J., Jr, Warren L. A., Novotny W. F., Higuchi D. A., Girard J. J., Miletich J. P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988 Feb;71(2):335–343. [PubMed] [Google Scholar]
  7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  8. Creasey A. A., Chang A. C., Feigen L., Wün T. C., Taylor F. B., Jr, Hinshaw L. B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993 Jun;91(6):2850–2860. doi: 10.1172/JCI116529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Day K. C., Hoffman L. C., Palmier M. O., Kretzmer K. K., Huang M. D., Pyla E. Y., Spokas E., Broze G. J., Jr, Warren T. G., Wun T. C. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood. 1990 Oct 15;76(8):1538–1545. [PubMed] [Google Scholar]
  10. Diaz-Collier J. A., Palmier M. O., Kretzmer K. K., Bishop B. F., Combs R. G., Obukowicz M. G., Frazier R. B., Bild G. S., Joy W. D., Hill S. R. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost. 1994 Mar;71(3):339–346. [PubMed] [Google Scholar]
  11. Drake T. A., Morrissey J. H., Edgington T. S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989 May;134(5):1087–1097. [PMC free article] [PubMed] [Google Scholar]
  12. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  13. Holdsworth S. R., Thomson N. M., Glasgow E. F., Dowling J. P., Atkins R. C. Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. J Exp Med. 1978 Jan 1;147(1):98–109. doi: 10.1084/jem.147.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huang X. R., Holdsworth S. R., Tipping P. G. Evidence for delayed-type hypersensitivity mechanisms in glomerular crescent formation. Kidney Int. 1994 Jul;46(1):69–78. doi: 10.1038/ki.1994.245. [DOI] [PubMed] [Google Scholar]
  15. Khouri R. K., Koudsi B., Kaiding F., Ornberg R. L., Wun T. C. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg. 1993 May;30(5):398–404. doi: 10.1097/00000637-199305000-00002. [DOI] [PubMed] [Google Scholar]
  16. Kincaid-Smith P. Coagulation and renal disease. Kidney Int. 1972 Oct;2(4):183–190. doi: 10.1038/ki.1972.93. [DOI] [PubMed] [Google Scholar]
  17. Kloth S., Schmidbauer A., Kubitza M., Weich H. A., Minuth W. W. Developing renal microvasculature can be maintained under perfusion culture conditions. Eur J Cell Biol. 1994 Feb;63(1):84–95. [PubMed] [Google Scholar]
  18. Malliaros J., Holdsworth S. R., Wojta J., Erlich J., Tipping P. G. Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int. 1993 Sep;44(3):557–564. doi: 10.1038/ki.1993.281. [DOI] [PubMed] [Google Scholar]
  19. McCluskey R. T., Vassalli P., Gallo G., Baldwin D. S. An immunofluorescent study of pathogenic mechanisms in glomerular diseases. N Engl J Med. 1966 Mar 31;274(13):695–701. doi: 10.1056/NEJM196603312741301. [DOI] [PubMed] [Google Scholar]
  20. Novotny W. F., Brown S. G., Miletich J. P., Rader D. J., Broze G. J., Jr Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 1991 Jul 15;78(2):387–393. [PubMed] [Google Scholar]
  21. Osterud B., Bajaj M. S., Bajaj S. P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995 May;73(5):873–875. [PubMed] [Google Scholar]
  22. Palmier M. O., Hall L. J., Reisch C. M., Baldwin M. K., Wilson A. G., Wun T. C. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost. 1992 Jul 6;68(1):33–36. [PubMed] [Google Scholar]
  23. Rapaport S. I. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood. 1989 Feb;73(2):359–365. [PubMed] [Google Scholar]
  24. Sandset P. M., Abildgaard U. Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis. 1991;21(4):219–239. doi: 10.1159/000216231. [DOI] [PubMed] [Google Scholar]
  25. Sandset P. M., Abildgaard U., Larsen M. L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988 Jun 15;50(6):803–813. doi: 10.1016/0049-3848(88)90340-4. [DOI] [PubMed] [Google Scholar]
  26. Sandset P. M., Warn-Cramer B. J., Maki S. L., Rapaport S. I. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood. 1991 Sep 15;78(6):1496–1502. [PubMed] [Google Scholar]
  27. Sandset P. M., Warn-Cramer B. J., Rao L. V., Maki S. L., Rapaport S. I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):708–712. doi: 10.1073/pnas.88.3.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Thomas P. E., Wharram B. L., Goyal M., Wiggins J. E., Holzman L. B., Wiggins R. C. GLEPP1, a renal glomerular epithelial cell (podocyte) membrane protein-tyrosine phosphatase. Identification, molecular cloning, and characterization in rabbit. J Biol Chem. 1994 Aug 5;269(31):19953–19962. [PubMed] [Google Scholar]
  29. Thomson N. M., Moran J., Simpson I. J., Peters D. K. Defibrination with ancrod in nephrotoxic nephritis in rabbits. Kidney Int. 1976 Nov;10(5):343–347. doi: 10.1038/ki.1976.120. [DOI] [PubMed] [Google Scholar]
  30. Thomson N. M., Simpson I. J., Peters D. K. A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis. Clin Exp Immunol. 1975 Feb;19(2):301–308. [PMC free article] [PubMed] [Google Scholar]
  31. Tipping P. G., Erlich J. H., Apostolopoulos J., Mackman N., Loskutoff D., Holdsworth S. R. Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol. 1995 Dec;147(6):1736–1748. [PMC free article] [PubMed] [Google Scholar]
  32. Tipping P. G., Holdsworth S. R. The participation of macrophages, glomerular procoagulant activity, and factor VIII in glomerular fibrin deposition. Studies on anti-GBM antibody-induced glomerulonephritis in rabbits. Am J Pathol. 1986 Jul;124(1):10–17. [PMC free article] [PubMed] [Google Scholar]
  33. Tipping P. G., Leong T. W., Holdsworth S. R. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest. 1991 Sep;65(3):272–279. [PubMed] [Google Scholar]
  34. Tipping P. G., Lowe M. G., Holdsworth S. R. Glomerular interleukin 1 production is dependent on macrophage infiltration in anti-GBM glomerulonephritis. Kidney Int. 1991 Jan;39(1):103–110. doi: 10.1038/ki.1991.13. [DOI] [PubMed] [Google Scholar]
  35. Tipping P. G., Lowe M. G., Holdsworth S. R. Glomerular macrophages express augmented procoagulant activity in experimental fibrin-related glomerulonephritis in rabbits. J Clin Invest. 1988 Oct;82(4):1253–1259. doi: 10.1172/JCI113723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tipping P. G., Thomson N. M., Holdsworth S. R. A comparison of fibrinolytic and defibrinating agents in established experimental glomerulonephritis. Br J Exp Pathol. 1986 Aug;67(4):481–491. [PMC free article] [PubMed] [Google Scholar]
  37. Tipping P. G., Worthington L. A., Holdsworth S. R. Quantitation and characterization of glomerular procoagulant activity in experimental glomerulonephritis. Lab Invest. 1987 Feb;56(2):155–159. [PubMed] [Google Scholar]
  38. Warn-Cramer B. J., Maki S. L. Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma. Thromb Res. 1992 Aug 15;67(4):367–383. doi: 10.1016/0049-3848(92)90267-e. [DOI] [PubMed] [Google Scholar]
  39. Warn-Cramer B. J., Rao L. V., Maki S. L., Rapaport S. I. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost. 1988 Dec 22;60(3):453–456. [PubMed] [Google Scholar]
  40. Warshawsky I., Bu G., Mast A., Saffitz J. E., Broze G. J., Jr, Schwartz A. L. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest. 1995 Apr;95(4):1773–1781. doi: 10.1172/JCI117855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Werling R. W., Zacharski L. R., Kisiel W., Bajaj S. P., Memoli V. A., Rousseau S. M. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost. 1993 Apr 1;69(4):366–369. [PubMed] [Google Scholar]
  42. van der Logt C. P., Dirven R. J., Reitsma P. H., Bertina R. M. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis. 1994 Apr;5(2):211–220. doi: 10.1097/00001721-199404000-00009. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES